

# **Prazosin boosts threat discrimination via effects on the safe stimulus**

Philipp Homan<sup>1</sup>, Qi Lin<sup>1</sup>, James W. Murrough<sup>1,2</sup>,  
Laili Soleimani<sup>1</sup>, Dominik R. Bach<sup>3</sup>, Roger L. Clem<sup>2</sup>, Daniela Schiller<sup>1,2\*</sup>

<sup>1</sup>Department of Psychiatry and Friedman Brain Institute,  
Icahn School of Medicine at Mount Sinai  
1470 Madison Ave, NY, NY 10029, USA.

<sup>2</sup>Department of Neuroscience and Friedman Brain Institute,  
Icahn School of Medicine at Mount Sinai  
1470 Madison Ave, NY, NY 10029, USA.

<sup>3</sup>Department of Psychiatry, Psychotherapy, and Psychosomatics  
University of Zurich, Zurich, Switzerland

\*To whom correspondence should be addressed; E-mail: daniela.schiller@mssm.edu.

Word count: 2325

## **Financial support**

Funding was provided by NIMH grant MH105515 and a Klingenstein-Simons Fellowship Award in the Neurosciences to D.S.; NIMH grant MH105414 to R.L.C.; and Swiss National Science Foundation grant SNF 161077 to P.H. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Keywords:** Prazosin; noradrenaline, threat; fear conditioning; extinction; memory; PTSD

## **Abstract**

The alpha-1 adrenoreceptor antagonist prazosin has shown promise in the treatment of some posttraumatic stress disorder (PTSD) symptoms, but its mechanisms are not well understood. Here we administered prazosin or placebo prior to threat conditioning (day 1) and tested subsequent extinction (day 2) and re-extinction (day 3) in healthy human participants. Prazosin did not affect threat conditioning but augmented stimulus discrimination during extinction and re-extinction, via lower responding to the safe stimulus. These results suggest that prazosin during threat acquisition may have influenced safety processing in particular, subsequently leading to enhanced discrimination between the safe and threatening stimuli.

Pavlovian threat conditioning is a prominent model for understanding the neural basis of threat memory and discrimination in posttraumatic stress disorder (PTSD). This model assumes that a conditioned stimulus (CS+, a formerly neutral stimulus such as a shape or a sound) is associated with an unconditioned stimulus (US, the aversive event) during threat learning, enabling the CS+ itself to become an unsafe cue and trigger a defensive response, while leaving unaffected a control stimulus (CS-, a safe cue) that had never been paired with the US. The effect of threat learning can be quantified by the amount of discrimination between the unsafe and the safe cue during threat conditioning. Subsequent presentations of the CS+ without the US induce extinction learning, a core process presumably underlying exposure therapy for PTSD (McLean and Foa, 2011).

The alpha-1 adrenergic receptor antagonist prazosin has shown promise in the treatment of PTSD. Prazosin attenuates noradrenaline effects at central postsynaptic alpha-1 adrenergic receptor after peripheral administration (Menkes *et al.*, 1981) and has been shown to reduce PTSD symptoms including nightmares, poor sleep quality, hyperarousal, and impaired global function (Ahmadpanah *et al.*, 2014; George *et al.*, 2016; Germain *et al.*, 2012; Raskind *et al.*, 2000, 2002, 2003, 2007, 2013; Taylor *et al.*, 2008) which may involve abnormally heightened activity of the noradrenergic central nervous system (Raskind *et al.*, 2016; Southwick *et al.*, 1993).

Previous threat conditioning studies in humans have shown that learned threat memory resisted extinction training following enhancement of noradrenergic activity while the initial learning of threat was unaffected (Soeter and Kindt, 2011, 2012). This suggests that threat discrimination learned under prazosin, and thus under attenuated noradrenergic activity,

should reverse this effect: compared to placebo, this discrimination should be unaffected during acquisition but easier to subsequently extinguish. Contrary to this prediction, however, studies in rodents found that alpha-1 adrenoreceptor antagonists enhanced threat acquisition and impaired threat extinction (Bernardi and Lattal, 2010; Cain *et al.*, 2006; Do-Monte *et al.*, 2010; Lazzaro *et al.*, 2010), raising the concerning possibility that prazosin might in fact work against extinction-based treatments (Do-Monte *et al.*, 2010; Maren, 2011).

To clarify the effects of prazosin on emotional memories in humans, we used a randomized double-blind between-within-subjects experimental design over three consecutive days (Fig. 1): Threat learning on day 1, threat extinction on day 2, and re-extinction test on day 3; the re-extinction test examined whether participants retrieve the learned threat discrimination (learned on day 1) or the extinction memory (learned on day 2). On day 1 (acquisition), participants were randomly assigned to receive either placebo or 3 mg of prazosin (1 mg capsule followed by 2 mg capsule 30 min later) two hours before threat acquisition (at the expected peak plasma prazosin level). Immediately before and every 30 minutes until 90 minutes after the administration of the study drug, blood pressure and heart rate were measured. In addition, we measured the trait anxiety subscale of the Spielberger State-Trait Anxiety Inventory (STAIT; Spielberger *et al.* 1983) before the experiment. Forty healthy human participants provided written informed consent and were compensated. The experiment was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. The final sample consisted of 38 participants, one of which did not show up for the third day (Table 1).

During threat conditioning, two colored squares were presented for 4 s on each trial, one of which was paired with a mild electric shock in 43% of the trials (CS+) while the other was never paired with a shock (CS-). On day 2 (extinction) and day 3 (re-extinction) no shocks were delivered but the stimulating bar electrodes were connected to the participant's non-dominant wrist. Skin conductance response (SCR) to the stimuli was measured throughout with Ag-AgCl electrodes, filled with standard NaCl electrolyte gel, and attached to the middle phalanges of the second and third fingers of the non-dominant hand. SCR signal was amplified and recorded with a MP150 BIOPAC Systems skin conductance module connected to a PC. Data were continuously recorded at a rate of 200 samples per second. Shocks were delivered using a Grass Medical Instruments SD9 stimulator and stimulating bar electrodes attached to the participant's non-dominant wrist. Shock intensity was calibrated up to a maximum of 60V to reach a level described by participants as "uncomfortable, but not painful".

The outcome measure was the psychophysiological arousal response to the CSs, indexed by the estimated anticipatory sudomotor nerve activity (aSNA) amplitude (Bach *et al.*, 2010). Estimates of aSNA indicate the anticipation of an aversive event within the time window of stimulus presentation. These were calculated by inverting a forward model that describes how (hidden) SNA translates into an (observable) SCR using a variational Bayes approximation. A unit increase in aSNA corresponds to an increase in SCR of 1  $\mu$  S. This method uses summary statistics across all available trials to demonstrate successful experimental manipulations such as threat conditioning, and has shown to be more sensitive

compared to a conventional SCR peak-to-peak analysis (Bach, 2014; Bach *et al.*, 2010, 2015; Staib *et al.*, 2015).

We used linear mixed models with restricted maximum likelihood estimation for all analyses, due to their well-established advantages over conventional analysis of variance (e.g., Gueorguieva and Krystal, 2004). Mixed models efficiently allow for a full analysis of the data even in the presence of missing data. We used the estimates of aSNA as outcome measure and the R software (R Core Team, 2016) and the packages lme4 (Baayen *et al.*, 2008; Bates *et al.*, 2015; Bates, 2005) and lsmeans (Lenth, 2016) for all analyses. Fixed effects included drug (placebo, prazosin), session (acquisition, extinction, re-extinction) and stimulus (CS+, CS-) as well as their interactions. In addition, a mean-centered linear term for trial was entered to account for the time-effect in each session. Significance of fixed effects was assessed using likelihood ratio tests against a  $\chi^2$  distribution and maximum likelihood as estimation method. A maximal random effects structure including random intercept and slopes for session and stimulus was included to avoid inflated type-1 errors (Barr *et al.*, 2013). Random slopes for session, stimulus, and the session x stimulus interaction for each subject were included to account for random variation between subjects' in the effects of interest. An unstructured variance-covariance matrix was used to allow for correlation between the random effects. The significance threshold was set at .05, two-tailed.

To assess whether there were group differences in threat discrimination in any of the sessions, we tested for an interaction of drug (placebo, prazosin) x session (acquisition, extinction, re-extinction) x stimulus. (CS+, CS-) and found that this interaction was significant ( $\chi^2(2) = 7.26, P = .03$ ; Fig. 1) and driven by enhanced stimulus discrimination (CS+ minus

CS-) in the prazosin group compared to placebo during extinction and re-extinction but not acquisition (Fig. 2). Specifically, both groups showed successful acquisition, indicated by stronger response to the CS+ compared to the CS- during acquisition and effect sizes between medium and large (Placebo:  $t(18) = 2.9$ ,  $P = 0.0097$ ; Cohen's  $d = 0.66$ ; Prazosin:  $t(18) = 4.1$ ,  $P = 0.0007$ ; Cohen's  $d = 0.94$ ). However, in the placebo group, the stimulus discrimination was not significant during extinction ( $t(18) = 1.55$ ,  $P = 0.14$ ) and re-extinction ( $t(17) = 1.3$ ,  $P = 0.21$ ) whereas for the prazosin group, it remained significant in extinction ( $t(18) = 5.04$ ,  $P = 0.0001$ ) and re-extinction ( $t(18) = 4.76$ ,  $P = 0.0002$ ; Fig. 2), confirming the 3-way interaction. These results indicate that threat acquisition was successful with no group differences, but stimulus discrimination differed between the groups during extinction and re-extinction, with augmented discrimination in the prazosin compared to the placebo group.

Next, we asked whether changes in response to one stimulus in particular drove the discrimination. We found that responses to the CS- were significantly lower in the prazosin group compared to the placebo group in extinction ( $t(36.04) = 2.24$ ,  $P = 0.031$ ) and re-extinction ( $t(34.05) = 2.9$ ,  $P = 0.007$ ) but not acquisition ( $t(39.74) = -0.44$ ,  $P = 0.66$ ), whereas CS+ did not significantly differ between groups in any session (all  $P > 0.84$ ) or phase within sessions (all  $P > 0.71$ ). These results indicate that prazosin boosts threat discrimination during extinction and re-extinction via effects on the safe stimulus.

Thus, prazosin effects during threat memory formation may change the fate of memory: threat discrimination learned under prazosin would be stronger and harder to extinguish over time. Consistent with the rodent data (i.e., potentiating threat memory), and in contrast the expected effects of noradrenergic activity blockade in humans (i.e., reducing

threat memory), we found that the prazosin group compared to placebo showed enhanced threat discrimination memory during extinction and re-extinction, driven by lower responding to the safe stimuli, with no effects during acquisition.

These findings are clinically relevant as prazosin is often prescribed for the treatment of PTSD symptoms (Ahmadpanah *et al.*, 2014; George *et al.*, 2016; Germain *et al.*, 2012; Raskind *et al.*, 2000, 2002, 2003, 2007, 2013; Taylor *et al.*, 2008), and prolonged exposure therapy is currently the most effective behavioral therapy in PTSD (McLean and Foa, 2011). If substantial residual symptoms remain (Raskind *et al.*, 2013), requiring additional behavioral therapy, prazosin may interact with such treatment. Prazosin might also augment the memory of negative experiences (or traumatic re-experiencing) during the course of treatment. Such effects may be related to recent evidence including the largest study conducted so far suggesting no benefit of prazosin over placebo on PTSD symptoms (Petrakis *et al.*, 2016; Davidson, 2016).

An important framework for this understanding is the close relationship between enhanced sympathetic activity and the pathophysiology of PTSD (Southwick *et al.*, 1993, 1999). After stimulation of the noradrenergic system with the alpha-2 antagonist yohimbine, a subgroup of PTSD patients showed acute symptoms including panic attacks, flashbacks, and intrusive traumatic thoughts (Southwick *et al.*, 1993). Elevated noradrenaline in the prefrontal cortex may add to these symptoms by stimulating alpha-1 adrenergic receptor and promoting amygdala disinhibition (Arnsten *et al.*, 2015). In addition, studies in animals have shown that the disruption of normal sleep by alpha-1 adrenergic receptor stimulation may be reversed by prazosin (Hilakivi and Leppavuori, 1984; Kleinlogel, 1989; Pellejero *et al.*, 1984; Pickworth



*et al.*, 1977). It has therefore been hypothesized that PTSD patients might benefit from attenuating the central noradrenergic activity by blocking the alpha-1 adrenergic receptor. Indeed, prazosin has been successfully used to treat nightmares and sleep disturbances (Ahmadpanah *et al.*, 2014; George *et al.*, 2016; Germain *et al.*, 2012; Raskind *et al.*, 2000, 2002, 2003, 2007, 2013; Taylor *et al.*, 2008).

How can prazosin interfere with extinction? Potentially, prazosin acts upon the encoding of the memory, affecting shared mechanisms, which are later recruited for extinction (Clem and Schiller, 2016). Some clues may arise from evaluating the effects of prazosin on threat learning and extinction, especially since alpha-1 adrenergic receptors are abundant in the lateral nucleus of the amygdala (LA), a key region of synaptic plasticity in threat learning and extinction (LeDoux, 2000). The LA receives inputs from the locus coeruleus that contain noradrenaline and exhibit tonic and phasic firing in response to aversive stimuli (Tully and Bolshakov, 2010). However, the role of noradrenaline in the modulation of threat learning is less clear. On the one hand, it has been shown that noradrenaline may suppress feed-forward inhibition of threat conditioning thalamic pathway, thereby enhancing learning-related plasticity (Ehrlich *et al.*, 2009; Tully *et al.*, 2007). On the other hand, alpha-1 adrenergic receptors in the LA may inhibit descending output from the central nucleus of the amygdala to brain regions controlling arousal and defensive responses (Braga *et al.*, 2004; Pape and Pare, 2010).

Rodent studies indicate that prazosin may in fact reduce amygdala's inhibitory tone (Bernardi and Lattal, 2010; Cain *et al.*, 2006; Do-Monte *et al.*, 2010; Lazzaro *et al.*, 2010). Thus, although alpha-1 adrenergic receptor blockade during threat learning is an unlikely

model for PTSD since it should counteract symptoms induced by elevated sympathetic activity, prazosin may capture certain conditions and individual differences in alpha-1 adrenergic receptor activity during the experience of a traumatic event, which may affect the development of PTSD in interesting and important ways. The current results indeed suggest that learning threat discrimination under prazosin is less flexible and better remembered over time.

Lower responding to the CS- but not CS+ drove the effect of prazosin on threat discrimination. Although it may seem as if prazosin augmented memory for the safe stimulus without affecting threat memory, a few considerations should be noted. The discrimination between safe and unsafe cues is adaptive only during acquisition when threat is imminent. During extinction, both cues are safe and the learned discrimination is no longer adaptive. A recent meta-analysis (Duits *et al.*, 2015) showed that anxiety patients exhibit less discrimination than controls in acquisition (when it is adaptive) and more discrimination in extinction (when it is maladaptive). Our results show that the prazosin group, but not placebo, persistently maintained the discrimination between the CS+ and the CS-, never fully extinguishing the difference between the stimuli despite two consecutive extinction sessions, which is maladaptive. It might be problematic, therefore, to argue that prazosin has positive effects by augmenting memory for safety learning when the net result is abnormally persistent threat discrimination. Nevertheless, to fully disentangle these competing interpretations, future studies should examine administration of prazosin prior to extinction, when the CS+ undergoes safety learning, and examine whether this would diminish or augment subsequent stimulus discrimination. Consistent with the latter possibility, rodent studies found

impairments in extinction learning when prazosin was administered prior to extinction training (Do-Monte *et al.*, 2010) and between repeated extinction sessions (Bernardi and Lattal, 2010), indicating it does not enhance but rather counteracts safety learning.

In conclusion, this study suggests that the otherwise promising effects of prazosin on PTSD symptoms might still warrant the monitoring of unwanted interactions with behavioral therapy if prazosin is combined with or followed by extinction-based treatments, as it might augment re-experienced memories or influence new memories of negative events acquired after therapy commences.

## **Acknowledgements**

Author Contributions: Dr. Homan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Homan, Lin, Soleimani, Murrough, Clem, Schiller. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Homan, Schiller. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Homan, Bach, Schiller. Obtaining funding: Homan, Clem, Schiller. Administrative, technical, or material support: Schiller. Study supervision: Schiller. The authors declare no competing financial interests. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.

## **Conflict of interest**

Dr. Murrough declares no conflicts related to the current study. In the past 3 years, Dr. Murrough has provided consultation services to Novartis, Janssen Research and Development, and Genentech; he is named on patents pending for neuropeptide Y as a treatment for mood and anxiety disorders, a patent pending for the combination of ketamine and lithium for suicidal ideation, and a patent pending for ketamine plus lithium to extend the antidepressant response of ketamine. Dr. Homan declares no conflicts related to the current study. Dr. Homan has received speaker's fees from Neurolite and Takeda Pharma in the past 3 years. All other authors report no conflicts of interest.

## References

- Ahmadpanah M, Sabzeiee P, Hosseini SM, Torabian S, Haghighi M, Jahangard L, Bajoghli H, Holsboer-Trachsler E, Brand S** (2014). Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. *Neuropsychobiology* **69**, 235–242.
- Arnsten AF, Raskind MA, Taylor FB, Connor DF** (2015). The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. *Neurobiology of Stress* **1**, 89–99.
- Baayen R, Davidson D, Bates D** (2008). Mixed-effects modeling with crossed random effects for subjects and items. *Journal of Memory and Language* **59**, 390–412.
- Bach DR** (2014). A head-to-head comparison of scralyze and ledalab, two model-based methods for skin conductance analysis. *Biological Psychology* **103**, 63–68.
- Bach DR, Daunizeau J, Friston KJ, Dolan RJ** (2010). Dynamic causal modelling of anticipatory skin conductance responses. *Biological Psychology* **85**, 163–170.
- Barr DJ, Levy R, Scheepers C, Tily HJ** (2013). Random effects structure for confirmatory hypothesis testing: Keep it maximal. *Journal of Memory and Language* **68**, 255–278.
- Bates D, Mächler M, Bolker B, Walker S** (2015). Fitting linear mixed-effects models using lme4. *Journal of Statistical Software* **67**, 1–48.
- Bates DM** (2005). Fitting linear mixed models in r. *R News* **5**, 27–30.

**Bernardi RE, Lattal KM** (2010). A role for  $\alpha_1$ -adrenergic receptors in extinction of conditioned fear and cocaine conditioned place preference. *Behavioral Neuroscience* **124**, 204–210.

**Braga MF, Aroniadou-Anderjaska V, Manion ST, Hough CJ, Li H** (2004). Stress impairs alpha(1a) adrenoceptor-mediated noradrenergic facilitation of gabaergic transmission in the basolateral amygdala. *Neuropsychopharmacology* **29**, 45–58.

**Cain CK, Bush DE, LeDoux JE** (2006). Prazosin, an  $\alpha_1$ -adrenergic receptor antagonist, enhances acquisition and impairs extinction of pavlovian cue fear. In *Proceedings from the 2006 Neuroscience Meeting Society for Neuroscience*. Atlanta, GA.

**Clem RL, Schiller D** (2016). New learning and unlearning: Strangers or accomplices in threat memory attenuation? *Trends in Neurosciences* **39**, 340–351.

**Davidson J** (2016). Pharmacotherapy of post-traumatic stress disorder: Going beyond the guidelines. *British Journal of Psychiatry Open* **2**, e16–e18.

**Do-Monte FH, Allensworth M, Carobrez AP** (2010). Impairment of contextual conditioned fear extinction after microinjection of alpha-1-adrenergic blocker prazosin into the medial prefrontal cortex. *Behavioural Brain Research* **211**, 89–95.

**Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, van den Hout MA, Baas JMP** (2015). Updated meta-analysis of classical fear conditioning in the anxiety disorders. *Depression and Anxiety* **32**, 239–253.

**Ehrlich I, Humeau Y, Grenier F, Ciochi S, Herry C, Lüthi A** (2009). Amygdala inhibitory circuits and the control of fear memory. *Neuron* **62**, 757–771.

- George KC, Kebejian L, Ruth LJ, Miller CW, Himelhoch S** (2016). Meta-analysis of the efficacy and safety of prazosin versus placebo for the treatment of nightmares and sleep disturbances in adults with posttraumatic stress disorder. *J Trauma Dissociation* **17**, 494–510.
- Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA** (2012). Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in us military veterans. *Journal of Psychosomatic Research* **72**, 89–96.
- Gueorguieva R, Krystal JH** (2004). Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. *Archives of General Psychiatry* **61**, 310-317.
- Halekoh U, Højsgaard S** (2014). A kenward-roger approximation and parametric bootstrap methods for tests in linear mixed models - the r package pbkrtest. *Journal of Statistical Software* **59**, 1–32.
- Hilakivi I, Leppavuori A** (1984). Effects of methoxamine, and alpha-1 adrenoceptor agonist, and prazosin, an alpha-1 antagonist, on the stages of the sleep-waking cycle in the cat. *Acta Physiologica Scandinavica* **120**, 363–372.
- Kleinlogel H** (1989). Effects of the selective alpha 1-adrenoceptor blocker prazosin on eeg sleep and waking stages in the rat. *Neuropsychobiology* **21**, 100–103.
- Kredlow MA, Unger LD, Otto MW** (2016). Harnessing reconsolidation to weaken fear and appetitive memories: A meta-analysis of post-re-extinction extinction effects. *Psychological Bulletin* **142**, 314–36.

- Lazzaro SC, Hou M, Cunha C, LeDoux JE, Cain CK** (2010). Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation. *Learning & Memory* **17**, 489–493.
- LeDoux JE** (2000). Emotion circuits in the brain. *Annual Review of Neuroscience* **23**, 155–184.
- Lenth RV** (2016). Least-squares means: The r package lsmeans. *Journal of Statistical Software* **69**, 1–33.
- Maren S** (2011). Seeking a spotless mind: Extinction, deconsolidation, and erasure of fear memory. *Neuron* **70**, 830–845.
- McLean CP, Foa EB** (2011). Prolonged exposure therapy for post-traumatic stress disorder: a review of evidence and dissemination. *Expert Review of Neurotherapeutics* **11**, 1151–1163.
- Menkes DB, Baraban JM, Aghajanian GK** (1981). Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoceptors in brain. *Naunyn-Schmiedeberg's Archives of Pharmacology* **317**, 273–275.
- Pape HC, Pare D** (2010). Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. *Physiological Reviews* **90**, 419–463.
- Pellejero T, Monti JM, Baglietto J, Jantos H, Pazos S, Cichevski V, Hawkins M** (1984). Effects of methoxamine and alpha-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat. *Sleep* **7**, 365–372.
- Petrakis IL, Desai N, Gueorguieva R, Arias A, O'Brien E, Jane JS, Sevarino K, Southwick S, Ralevski E** (2016). Prazosin for veterans with posttraumatic stress disorder and



comorbid alcohol dependence: A clinical trial. *Alcoholism: Clinical and Experimental Research* **40**, 178–186.

**Pickworth WB, Sharpe LG, Nozaki M, Martin WR** (1977). Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog. *Experimental Neurology* **57**, 999–1011.

**R Core Team** (2016). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria.

**Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER** (2000). The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. *Journal of Clinical Psychiatry* **61**, 129–133.

**Raskind MA, Millard SP, Petrie EC, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Hill J, Daniels C, Hendrickson R, Peskind ER** (2016). Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. *Biological Psychiatry* **80**, 736–742.

**Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O’Connell J, Taylor F, Gross C, Rohde K, McFall ME** (2007). A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. *Biological Psychiatry* **61**, 928–934.

**Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, Thomas RG, McFall MM** (2003). Reduction of nightmares and other ptsd symptoms in combat veterans by prazosin: A placebo-controlled study. *American Journal of Psychiatry* **160**, 371–373.

**Raskind MA, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Homas D, Hill J, Daniels C, Calohan J, Millard SP, Rohde K, O'Connell J, Pritzl D, Feiszli K, Petrie EC, Gross C, Mayer CL, Freed MC, Engel C, Peskind ER** (2013). A trial of prazosin for combat trauma ptsd with nightmares in active-duty soldiers returned from iraq and afghanistan. *American Journal of Psychiatry* **170**, 1003–110.

**Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall ME, Peskind ER** (2002). Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. *Journal of Clinical Psychiatry* **63**, 565–568.

**Rothbaum BO, Davis M** (2002). Exposure therapy for posttraumatic stress disorder. *American Journal of Psychotherapy* **56**, 59–75.

**Schiller D, Delgado MR** (2010). Overlapping neural systems mediating extinction, reversal and regulation of fear. *Trends in Cognitive Sciences* **14**, 268–276.

**Schiller D, Levy I, Niv Y, Ledoux JE, Phelps EA** (2008). From fear to safety and back: reversal of fear in the human brain. *The Journal of Neuroscience* **28**, 11517–11525.

**Schiller D, Monfils MH, Raio CM, Johnson DC, Ledoux JE, Phelps EA** (2010). Preventing the return of fear in humans using reconsolidation update mechanisms. *Nature* **463**, 49–53.

**Soeter M, Kindt M** (2011). Noradrenergic enhancement of associative fear memory in humans. *Neurobiology of Learning and Memory* **96**, 263–271.

**Soeter M, Kindt M** (2012). Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. *Neuropsychopharmacology* **37**, 1204–1215.

**Southwick SM, Bremner J, Rasmusson A, Morgan CA, Arnsten A, Charney DS (1999).** Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. *Biological Psychiatry* **46**, 1192–1204.

**Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS (1993).** Abnormal noradrenergic function in posttraumatic stress disorder. *Archives of General Psychiatry* **50**, 266–274.

**Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983).** *Manual for the State-Trait Anxiety Inventory*. Palo Alto, CA: Consulting Psychologists Press.

**Staib M, Castegnetti G, Bach DR (2015).** Optimising a model-based approach to inferring fear learning from skin conductance responses. *Journal of Neuroscience Methods* **255**, 131–138.

**Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA (2008).** Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. *Biological Psychiatry* **63**, 629–632.

**Tully K, Bolshakov VY (2010).** Emotional enhancement of memory: How norepinephrine enables synaptic plasticity. *Molecular Brain* **3**, 15.

**Tully K, Li Y, Tsvetkov E, Bolshakov VY (2007).** Norepinephrine enables the induction of associative long-term potentiation at thalamo-amygdala synapses. *Proceedings of the National Academy of Sciences* **104**, 14146–14150.

**Warren VT, Anderson KM, Kwon C, Bosshardt L, Jovanovic T, Bradley B, Norrholm SD (2014).** Human fear extinction and return of fear using reconsolidation update


mechanisms: The contribution of on-line expectancy ratings. *Neurobiology of Learning and Memory* **113**, 165–173.

**Table 1: Demographics, behavioral and physiological measurements by group.**

<b>Characteristic</b>	<b>Placebo (N=19)</b>	<b>Prazosin (N=19)</b>
Age, mean (SD), y	27.2 (5.6)	26.3 (4.9)
Gender, (m/f)	7/12	9/10
Adverse events	1	2
Drop-outs	1	1
Heart rate baseline, mean (SD), beats/min	73.4 (10.3) <sup>a</sup>	77.8 (11.4) <sup>a</sup>
Heart rate 90 min, mean (SD), beats/min	66.4 (9.9)	72.4 (11.2) <sup>a</sup>
Systolic BP baseline, mean (SD), mm Hg	110.6 (8.4) <sup>a</sup>	112.2 (7.6) <sup>a</sup>
Diastolic BP baseline, mean (SD), mm Hg	66.4 (7.7) <sup>a</sup>	67.7 (8.6) <sup>a</sup>
Systolic BP 90 min, mean (SD), mm Hg	107.2 (10.5)	103.9 (11.6) <sup>a</sup>
Diastolic BP 90 min, mean (SD), mm Hg	67.8 (11.0)	67.2 (8.4) <sup>a</sup>
Shock intensity, mean (SD), V	4.2 (1.4)	4.2 (1.0) <sup>a</sup>
STAI-T total score, mean (SD)	32.7 (9.2) <sup>a</sup>	32.7 (9.1)


Two male participants were excluded before the experiment due to presumable side effects to the study drug: one male participant reported dizziness and nausea 30 minutes after ingestion of the placebo pill, another male participant developed a syncope for 5 seconds 1 minute after taking the first capsule (1 mg) of prazosin. One female participant experienced syncope approximately 5 hours after drug ingestion that lasted 3 minutes, but was willing to complete the study. Additional monitored side effects included blood pressure drops in two males and nosebleed in one female. The groups did not differ in the physiological response to the drug, there were no significant differences in trait anxiety or shock intensity levels, and the groups did not significantly differ in their physiological (SNA) responses to the shocks during threat learning. There was no significant influence of heart rate, blood pressure, trait anxiety and shock intensity (all  $P$ s > 0.16) when included as covariates in our model and our primary finding, the 3-way interaction, remained significant whenever an additional covariate was included. It is therefore unlikely that the physiological or psychological baseline measures influenced threat processing. As prazosin has a short half-life of only 3 hours, the results cannot be explained by direct action of prazosin in extinction or re-extinction, suggesting that noradrenaline may alter the long-term consequences of newly acquired threat associations.

*Abbreviations:* BP, blood pressure; STAI-T, trait anxiety subscale of the Spielberger State-Trait Anxiety Inventory; CS, conditioned stimulus. <sup>a</sup> Due to one missing value, the measure was calculated only for N=18 participants.



**Figure 1: Experimental design and behavioral results.** *Upper panel.* This was a randomized double-blind experimental design in healthy volunteers involving three consecutive days: Threat learning on day 1, threat extinction on day 2, and re-extinction test on day 3; the re-extinction test examined whether participants retrieve the threat discrimination (learned on day 1) or the extinction memory learned on day 2). On day 1 (acquisition), participants were randomly assigned to receive either placebo or 3 mg of prazosin (1 mg capsule followed by 2 mg capsule 30 min later) two hours before threat acquisition (at the expected peak plasma prazosin level). During threat conditioning, two colored squares were presented for 4 s on each trial, one of which was paired with a mild electric shock in 43% of the trials (CS+) while the other was never paired with a shock (CS-). On day 2 (extinction) and day 3 (re-extinction) no shocks were delivered but the stimulating bar electrodes were connected to the participant's non-dominant wrist. Extinction and re-

extinction started with a CS- presentation and thus involved one additional CS- (trial 0); subsequent presentations of CS+ and CS- were counterbalanced. *Abbreviations:* CS, conditioned stimulus; US, unconditioned stimulus; ITI, intertrial interval. *Bottom panel.* **Stimulus discrimination summarized by group and stage show successful acquisition for both groups but persisting stimulus discrimination (mediated by effects on the safe stimulus) in the prazosin group in extinction and re-extinction.** Mean logarithmized anticipatory sudomotor nerve activity estimates (aSNA) for acquisition, extinction, and re-extinction after administration of placebo and prazosin. Error bars denote standard errors. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .



**Figure 2: Planned contrasts for stimulus-discrimination differences between the prazosin and placebo groups for each session show effects specific for extinction and re-extinction but not acquisition.** Confidence intervals that do not include zero (cross the vertical dashed line) indicate that the corresponding contrast is statistically significant. Adjusted means (indicating the mean response for each factor, adjusted for any other variables in the model) with 95% confidence intervals for each drug, session, and stimulus were calculated from the multilevel model output, and used to test the stimulus-discrimination (CS+ minus CS-) differences between prazosin and placebo for each session. Specifically, during acquisition, there was no significant group x stimulus interaction ( $t(38.42) = -0.40, P = .69$ ), and there was evidence across groups for significant stimulus discrimination ( $t(38.42) = 4.07, P < .001$ ). In contrast, when examining the subsequent stages, we found a significant group x stimulus interaction during extinction ( $t(39.3) = 2.06, P = .046$ ) and re-extinction ( $t(38.42) = 2.86, P = .006$ ). *Abbreviations:* CS, conditioned stimulus; CI, confidence interval.